Pharmacological aspects of the combined use of 3,4- methylenedioxymethamphetamine (MDMA, ecstasy) and gamma-hydroxybutyric acid (GHB): A review of the literature

Drug and Alcohol Review

Volumn 24, Issue 4, 2005, Pages 359-368

  Uys, Joachim D K ^a,b   Niesink, Raymond J M ^a,c  

^a NETHERLANDS INSTITUTE OF MENTAL HEALTH AND ADDICTION   (Netherlands)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c NONE   (Netherlands)

Author keywords

Ecstasy; Gamma hydroxybutyrate; GHB; MDMA; Pharmacology; Polydrug use; Review

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXYBUTYRIC ACID; 4-HYDROXYBUTYRIC ACID; DOPAMINE; HYDROXYBUTYRIC ACID; NORADRENALIN; PSYCHEDELIC AGENT; SEROTONIN;

ADDICTION; ANXIETY; BODY TEMPERATURE; CHEMICALLY INDUCED DISORDER; DEPRESSION; DRUG EFFECT; HUMAN; METABOLISM; PSYCHOMOTOR DISORDER; REVIEW;

ANXIETY; BODY TEMPERATURE; DEPRESSION; DOPAMINE; HALLUCINOGENS; HUMANS; HYDROXYBUTYRATES; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NOREPINEPHRINE; PSYCHOMOTOR DISORDERS; SEROTONIN; SUBSTANCE-RELATED DISORDERS;

EID: 27844592691     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1080/09595230500295725     Document Type: Review

References (124)

1. Club Health 2002.The 2nd international conference on night-life substance use and related health issues. 24-27 March 2002, Fiera District Rimini, Italy.
2. Teter CJ, Guthrie SK. A comprehensive review of MDMA and GHB: two common club drugs. Pharmacotherapy 2001;21:1486 - 513.
3. Johnston LD, O'Malley PM, Bachman JG. 'Ecstasy' use rises sharply among teens in 2000. Accessed 1 February 2003. Available at: www.monitoringthefuture. org.
4. EMCDDA.The European Monitoring Centre for Drugs and Drug Addiction. Annual report on the state of the drugs problem in the European Union. Lisboa: EMCDDA 2002.
5. Bravo GL. What does MDMA feel like? In: Holland J, ed. Ecstasy: the complete guide. Rochester, Vermont: Park Street Press, 2001:21 - 8.
6. Vollenweider FX, Gamma A, Liechti M, Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA ('ecstasy') in MDMA-naive healthy volunteers. Neuropsychopharmacology 1998;19:241 - 51.
7. Cohen RS. Subjective reports on the effects of the MDMA ('ecstasy') experience in humans. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:1137 - 45.
8. Siegel RK. MDMA. Nonmedical use and intoxication. J Psychoact Drugs 1986;18:349 - 54.
9. Mas M, Farre M, de la Torre R, Roset PN, et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4- methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 1999;290:136 - 45.
10. Nichols DE. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoact Drugs 1986;18:305 - 13.
11. Gouzoulis-Mayfrank E, Hermle L, Kovar KA, Sass H. [Entactogenic drugs 'ecstasy' (MDMA), 'eve' (MDE) and other ring-substituted methamphetamine derivatives. A new class of substances among illegal designer drugs?]. Nervenarzt 1996;67:369 - 80.
12. Velea D, Hautefeuille M, Vazeille G, Lantran-Davoux C. Nouvelles drogues synthetiques empathogenes [New synthesis empathogenic agents]. Encephale 1999;25:508 - 14.
13. Dean W, Morgenthaler J, Fowkes SWM. GHB: the natural mood enhancer. Petaluma: Smart Publications, 1997.
14. Doyon S. The many faces of ecstasy. Curr Opin Pediatr 2001;13:170 - 6.
15. Haasen C. Patterns of consumption. Eur Addict Res 2001;7:1.
16. Tossmann P, Boldt S, Tensil MD. The use of drugs within the techno party scene in European metropolitan cities. Eur Addict Res 2001;7:2 - 23.
17. Winstock AR, Griffiths P, Stewart D. Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend 2001;64:9 - 17.
18. Cottler LB, Womack SB. Ecstasy abuse and dependence among adolescents and young adults: applicability and reliability of DSM-IV criteria. Hum Psychopharmacol Clin Exp 2001; 16:627 - 33.
19. Miotto K, Darakjian J, Basch J, Murray S, Zogg J, Rawson R. Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal. Am J Addict 2001;10:232 - 41.
20. Korf DJ, Nabben T, Leenders F, Benschop A. GHB: tussen extase en narcose. Amsterdam: Rozenberg Publishers, 2002.
21. Drug Abuse Warning Network. The DAWN report. Available at: http://www.samsha.gov/oms/dawn.hm. Accessed 6 April 2001.
22. Nabben T, Korf DJ. De combi-roes: gecombineerd gebruik van alcohol met cannabis, cocaine, XTC en amfetamine. Amsterdam: Rozenberg Publishers, 2000.
23. Maitre M. The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. Prog Neurobiol 1997;51:337 - 61.
24. Simantov R. Multiple molecular and neuropharmacological effects of MDMA (Ecstasy). Life Sci 2004;74:803 - 14.
25. Nava F, Carta G, Bortolato M, Gessa GL. gamma-Hydroxybutyric acid and baclofen decrease extracellular acetylcholine levels in the hippocampus via GABA(B) receptors. Eur J Pharmacol 2001;430:261 - 3.
26. Schmidt-Mutter C, Gobaille S, Muller C, Maitre M. Prodynorphin and proenkephalin mRNAs are increased in rat brain after acute and chronic administration of gamma-hydroxybutyrate. Neurosci Lett 1999;262:65 - 8.
27. Malberg JE, Bonson KR. How MDMA works in the brain. In: Holland J, ed. Ecstasy: the complete guide. Rochester, Vermont: Park Street Press, 2001:29 - 38.
28. Okun MS, Boothby LA, Bartfield RB, Doering PL. GHB: an important pharmacologic and clinical update. J Pharm Pharm Sci 2001;4:167 - 75.
29. Cole JC, Sumnall HR. The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Neurosci Biobehav Rev 2003;27:199 - 217.
30. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol Rev 2003;55:463 - 508.
31. Colado MI, O'Shea E, Green AR. Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function. Psychopharmacology (Berl) 2004;173:249 - 63.
32. Roth RH. Formation and regional distribution of gamma-hydroxybutyric acid in mammalian brain. Biochem Pharmacol 1970;19:3013 - 19.
33. Doherty JD, Hattox SE, Snead OC, Roth RH. Identification of endogenous gamma-hydroxybutyrate in human and bovine brain and its regional distribution in human, guinea pig and rhesus monkey brain. J Pharmacol Exp Ther 1978;207:130 - 9.
34. Cash CD. Gamma-hydroxybutyrate: an overview of the pros and cons for it being a neurotransmitter and/or a useful therapeutic agent. Neurosci Biobehav Rev 1994;18:291 - 304.
35. Laborit H. Sodium 4-Hydroxybutyrate. Int J Neuropharmacol 1964;32:433 - 51.
36. Bernasconi R, Mathivet P, Bischoff S, Marescaux C. Gamma-hydroxybutyric acid: an endogenous neuro-modulator with abuse potential? Trends Pharmacol Sci 1999;20:135 - 41.
37. Galloway GP, Frederick SL, Staggers F-EJ, Gonzales M, Stalcup SA, Smith DE. Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction 1997;92:89 - 96.
38. Wong CG, Gibson KM, Snead OC, III. From the street to the brain: neurobiology of the recreational drug gamma-hydroxybutyric acid. Trends Pharmacol Sci 2004;25:29 - 34.
39. Aghajanian GK, Marek GJ. Serotonin and hallucinogens. Neuropsychopharmacology 1999; 21 (Suppl 2):S16 - 23.
40. Oberlender R, Nichols DE. (+)-N-methyl-1-(1,3-benzodioxol-5-yl)- 2-butanamine as a discriminative stimulus in studies of 3,4-methylenedioxy- methamphetamine-like behavioural activity. J Pharmacol Exp Ther 1990;255:1098 - 106.
41. Green AR, Cross AJ, Goodwin GM. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy'). Psychopharmacology (Berl) 1995; 119:247 - 60.
42. Huether G, Zhou D, Ruther E. Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4- methylenedioxymethamphetamine (MDMA, 'ecstasy') and its congeners. J Neural Transm 1997;104:771 - 94.
43. Partilla JS, Dersch CM, Yu H, Rice KC, Rothman RB. Neurochemical neutralization of amphetamine-type stimulants in rat brain by the indatraline analog (-)-HY038. Brain Res Bull 2000;53:821 - 26.
44. Gu XF, Azmitia EC. Integrative transporter-mediated release from cytoplasmic and vesicular 5-hydroxytryptamine stores in cultured neurons. Eur J Pharmacol 1993;235:51 - 7.
45. Brodkin J, Malyala A, Nash JF. Effect of acute monoamine depletion on 3,4- methylenedioxymethamphetamine-induced neurotoxicity. Pharmacol Biochem Behav 1993;45:647 - 53.
46. Schmidt CJ, Levin JA, Lovenberg W. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem Pharmacol 1987;36:747 - 55.
47. Hekmatpanah CR, Peroutka SJ. 5-hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4- methylenedioxymethamphetamine and related agents. Eur J Pharmacol 1990;177:95 - 8.
48. White SR, Obradovic T, Imel KM, Wheaton MJ. The effects of methylenedioxymethamphetamine (MDMA, 'Ecstasy') on monoaminergic neurotransmission in the central nervous system. Prog Neurobiol 1996;49:455 - 79.
49. Gudelsky GA, Nash JF. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J Neurochem 1996;66:243 - 9.
50. Koch S, Galloway MP. MDMA induced dopamine release in vivo: role of endogenous serotonin. J Neural Transm 1997;104:135 - 46.
51. Fletcher PJ, Korth KM, Robinson SR, Baker GB. Multiple 5-HT receptors are involved in the effects of acute MDMA treatment: studies on locomotor activity and responding for conditioned reinforcement. Psychopharmacology (Berl) 2002;162:282 - 91.
52. Bengel D, Murphy DL, Andrews AM, et al. Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine ('Ecstasy') in serotonin transporter-deficient mice. Mol Pharmacol 1998;53:649 - 55.
53. Battaglia G, Brooks BP, Kulsakdinun C, de Souza EB. Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 1988;149:159 - 63.
54. Stone DM, Stahl DC, Hanson GR, Gibb JW. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol 1986;128:41 - 8.
55. Leonardi ET, Azmitia EC. MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology 1994;10:231 - 8.
56. Callaway CW, Wing LL, Geyer MA. Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats. J Pharmacol Exp Ther 1990;254:456 - 64.
57. Rempel NL, Callaway CW, Geyer MA. Serotonin 1B receptor activation mimics behavioural effects of presynaptic serotonin release. Neuropsychopharmacology 1993;8:201 - 11.
58. Nash JF Jr, Meltzer HY, Gudelsky GA. Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther 1988;245:873 - 9.
59. Liechti ME, Baumann C, Gamma A, Vollenweider FX. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 2000;22:513 - 21.
60. Liechti ME, Saur MR, Gamma A, Hell D, Vollenweider FX. Psychological and physiological effects of MDMA ('Ecstasy') after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacology 2000;23:396 - 404.
61. Liechti ME, Vollenweider FX. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol Clin Exp 2001;16:589 - 98.
62. Liechti ME, Geyer MA, Hell D, Vollenweider FX. Effects of MDMA (Ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin. Neuropsychopharmacology 2001;24:240 - 52.
63. Liechti ME, Vollenweider FX. The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4- methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers. J Psychopharmacol 2000;14:269 - 74.
64. Spano PF, Przegalinski E. Stimulation of serotonin synthesis by anesthetic and non-anesthetic doses of gamma-hydroxybutyrate. Pharmacol Res Commun 1973;5:55 - 69.
65. Waldmeier PC, Fehr B. Effects of baclofen and gamma-hydroxybutyrate on rat striatal and mesolimbic 5-HT metabolism. Eur J Pharmacol 1978;49:177 - 84.
66. Hedner T, Lundborg P. Effect of gammahydroxybutyric acid on serotonin synthesis, concentration and metabolism in the developing rat brain. J Neural Transm 1983;57:39 - 48.
67. Miguez I, Aldegunde M, Duran R, Veira JA. Effect of low doses of gamma-hydroxybutyric acid on serotonin, noradrenaline, and dopamine concentrations in rat brain areas. Neurochem Res 1988;13:531 - 3.
68. Gobaille S, Schleef C, Hechler V, Viry S, Aunis D, Maitre M. Gamma-hydroxybutyrate increases tryptophan availability and potentiates serotonin turnover in rat brain. Life Sci 2002;70:2101 - 12.
69. Malison RT, Best SE, Wallace EA, et al. Euphorigenic doses of cocaine reduce [123I]beta-CIT SPECT measures of dopamine transporter availability in human cocaine addicts. Psychopharmacology (Berl) 1995;122:358 - 62.
70. Volkow ND, Wang GJ, Fischman MW, et al. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 1997;386:827 - 30.
71. Wise SP, Murray EA, Gerfen CR. The frontal cortex-basal ganglia system in primates. Crit Rev Neurobiol 1996;10:317 - 56.
72. Kuhar MJ, Ritz MC, Boja JW. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 1991;14:299 - 302.
73. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988;85:5274 - 8.
74. Bilsky EJ, Montegut MJ, Nichols ML, Reid LD. CGS 10746B, a novel dopamine release inhibitor, blocks the establishment of cocaine and MDMA conditioned place preferences. Pharmacol Biochem Behav 1998;59:215 - 20.
75. Yamamoto BK, Nash JF, Gudelsky GA. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J Pharmacol Exp Ther 1995;273:1063 - 70.
76. Sasaki-Adams DM, Kelley AE. Serotonin-dopamine interactions in the control of conditioned reinforcement and motor behaviour. Neuropsychopharmacology 2001;25:440 - 52.
77. Gough B, Imam SZ, Blough B, Slikker W, Jr, Ali SF. Comparative effects of substituted amphetamines (PMA, MDMA, and METH) on monoamines in rat caudate: a microdialysis study. Ann NY Acad Sci 2002;965:410 - 20.
78. Kalivas PW, Duffy P, White SR. MDMA elicits behavioural and neurochemical sensitization in rats. Neuropsychopharmacology 1998;18:469 - 79.
79. Shankaran M, Gudelsky GA. Effect of 3,4-methylenedioxymethamphetamine (MDMA) on hippocampal dopamine and serotonin. Pharmacol Biochem Behav 1998;61:361 - 6.
80. Gough B, Ali SF, Slikker W, Jr, Holson RR. Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate. Pharmacol Biochem Behav 1991;39:619 - 23.
81. Schmidt CJ, Sullivan CK, Fadayel GM. Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. J Neurochem 1994;62:1382 - 9.
82. Nash JF, Brodkin J. Microdialysis studies on 3,4- methylenedioxymethamphetamine-induced dopamine release: effect of dopamine uptake inhibitors. J Pharmacol Exp Ther 1991;259:820 - 5.
83. Pan HS, Wang RY. MDMA: further evidence that its action in the medial prefrontal cortex is mediated by the serotonergic system. Brain Res 1991;539:332 - 6.
84. 3H] dopamine release from superfused rat brain slices. Eur J Pharmacol 1986;132:269 - 76.
85. Yamamoto BK, Spanos LJ. The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Eur J Pharmacol 1988;148:195 - 203.
86. White SR, Duffy P, Kalivas PW. Methylenedioxymethamphetamine depresses glutamate-evoked neuronal firing and increases extracellular levels of dopamine and serotonin in the nucleus accumbens in vivo. Neuroscience 1994;62:41 - 50.
87. Porrino LJ, Ritz MC, Goodman NL, Sharpe LG, Kuhar MJ, Goldberg SR. Differential effects of the pharmacological manipulation of serotonin systems on cocaine and amphetamine self-administration in rats. Life Sci 1989;45:1529 - 35.
88. Geyer MA, Callaway CW. Behavioural pharmacology of ring-substituted amphetamine analogs. In: Cho AK, Segal S, eds. Amphetamine and its analogs: psychopharmacology, toxicology, and abuse. New York: Academic Press, 1994:177 - 208.
89. Dafters RI, Lynch E. Persistent loss of thermoregulation in the rat induced by 3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy') but not by fenfluramine. Psychopharmacology (Berl) 1998,138:207 - 12.
90. Gordon CJ, Watkinson WP, O'Callaghan JP, Miller DB. Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat. Pharmacol Biochem Behav 1991;38:339 - 44.
91. Glennon RA, Yousif M, Patrick G. Stimulus properties of 1-(3,4-methylenedioxyphenyl)- 2-aminopropane (MDA) analogs. Pharmacol Biochem Behav 1988;29:443 - 9.
92. Hegadoren KM, Martin-Iverson MT, Baker GB. Comparative behavioural and neurochemical studies with a psychomotor stimulant, an hallucinogen and 3,4-methylenedioxy analogues of amphetamine. Psychopharmacology (Berl) 1995;118:295 - 304.
93. Gold LH, Geyer MA, Koob GF. Psychostimulant properties of MDMA. NIDA Res Monogr 1989;95:345 - 6.
94. Martinez-Price DL, Krebs-Thomson K, Geyer MA. Behavioural psychopharmacology of MDMA and MDMA-like drugs: a review of human and animal studies. Addict Res Theory 2002;10:43 - 67.
95. Bankson MG, Cunningham KA. 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions. J Pharmacol Exp Ther 2001;297:846 - 52.
96. Liechti ME, Vollenweider FX. Acute psychological and physiological effects of MDMA ('Ecstasy') after haloperidol pretreatment in healthy humans. Eur Neuropsychopharmacol 2000;10:289 - 95.
97. Howard SG, Banerjee PK. Regulation of central dopamine by y-hydroxybutyrate. In: Tunnicliff G, Cash CD, eds. Gamma-hydroxybutyrate. London: Taylor & Francis, 2002:111 - 19.
98. Nissbrandt H, Engberg G. The GABAB-receptor antagonist, CGP 35348, antagonises gamma-hydroxybutyrate-and baclofen-induced alterations in locomotor activity and forebrain dopamine levels in mice. J Neural Transm 1996;103:1255 - 63.
99. Carai MA, Colombo G, Reali R, et al. Central effects of 1,4-butanediol are mediated by GABA(B) receptors via its conversion into gamma-hydroxybutyric acid. Eur J Pharmacol 2002;441:157 - 63.
100. Pontieri FE, Tanda G, Di Chiara G. Intravenous cocaine, morphine, and amphetamine preferentially increase extra-cellular dopamine in the 'shell' as compared with the 'core' of the rat nucleus accumbens. Proc Natl Acad Sci USA 1995;92:12304 - 8.
101. Koob GF, Sanna PP, Bloom FE. Neuroscience of addiction. Neuron 1998;21:467 - 76.
102. Robbins TW, Everitt BJ. Drug addiction: bad habits add up. Nature 1999;398:567 - 70.
103. Ritz MC, Kuhar MJ. Relationship between self-administration of amphetamine and monoamine receptors in brain: comparison with cocaine. J Pharmacol Exp Ther 1989;248:1010 - 17.
104. Chen NH, Reith ME. Autoregulation and monoamine interactions in the ventral tegmental area in the absence and presence of cocaine: a microdialysis study in freely moving rats. J Pharmacol Exp Ther 1994;271:1597 - 610.
105. Chen NH, Reith ME. Effects of locally applied cocaine, lidocaine, and various uptake blockers on monoamine transmission in the ventral tegmental area of freely moving rats: a microdialysis study on monoamine interrelationships. J Neurochem 1994;63:1701 - 13.
106. Florin SM, Kuczenski R, Segal DS. Regional extracellular noradrenaline responses to amphetamine and cocaine and effects of clonidine pretreatment. Brain Res 1994;654:53 - 62.
107. Florin SM, Kuczenski R, Segal DS. Effects of reserpine on extracellular caudate dopamine and hippocampus noradrenaline responses to amphetamine and cocaine: mechanistic and behavioural considerations. J Pharmacol Exp Ther 1995;274:231 - 41.
108. Wang YM, Xu F, Gainetdinov RR, Caron MG. Genetic approaches to studying noradrenaline function: knockout of the mouse noradrenaline transporter gene. Biol Psychiatry 1999;46:1124 - 30.
109. Giros B, Wang YM, Suter S, McLeskey SB, Pifl C, Caron MG. Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-noradrenaline transporters. J Biol Chem 1994;269:15985 - 8.
110. Pacholczyk T, Blakely RD, Amara SG. Expression cloning of a cocaine- and antidepressant-sensitive human noradrenalinee transporter. Nature 1991;350:350 - 4.
111. Villemagne VL, Wong DF, Yokoi F, et al. GBR12909 attenuates amphetamine-induced striatal dopamine release as measured by [(11)C]raclopride continuous infusion PET scans. Synapse 1999;33:268 - 73.
112. Rothman RB, Baumann MH, Dersch CM, et al. Amphetamine-type central nervous system stimulants release noradrenaline more potently than they release dopamine and serotonin. Synapse 2001;39:32 - 41.
113. Fitzgerald JL, Reid JJ. Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices. Eur J Pharmacol 1990;191:217 - 20.
114. Lavelle A, Honner V, Docherty JR. Investigation of the prejunctional alpha2-adrenoceptor mediated actions of MDMA in rat atrium and vas deferens. Br J Pharmacol 1999,128:975 - 80.
115. Lester SJ, Baggott M, Welm S, et al. Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial. Ann Intern Med 2000;133:969 - 73.
116. 3H]monoamines into synaptosomes from different regions of rat brain. Biochem Pharmacol 1987;36:2297 - 303.
117. Griffiths RR, Bigelow G, Liebson I. Human drug self-administration: double-blind comparison of pentobarbital, diazepam, chlorpromazine and placebo. J Pharmacol Exp Ther 1979;210:301 - 10.
118. Brauer LH, de Wit H. Subjective responses to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers. Biol Psychiatry 1996;39:26 - 32.
119. Chait LD. Reinforcing and subjective effects of methyl-phenidate in humans. Behav Pharmacol 1994;5:281 - 8.
120. Vargiu L, Crabai F, Camba R, Gessa GL. [Effect of gamma-butyrolactone on the cerebral content of monamine]. Boll Soc Ital Biol Sper 1966;42:1633 - 4.
121. Gessa GL, Vargiu L, Crabai F, Boero GC, Caboni F, Camba R. Selective increase of brain dopamine induced by gamma hydroxybutyrate. Life Sci 1966;5:1921 - 30.
122. Hechler V, Gobaille S, Bourguignon JJ, Maitre M. Extracellular events induced by gamma-hydroxybutyrate in striatum: a microdialysis study. J Neurochem 1991;56:938 - 44.
123. Kaufman EE, Porrino LJ, Nelson T. Pyretic action of low doses of gamma-hydroxybutyrate in rats. Biochem Pharmacol 1990;40:2637 - 40.
124. Hernandez-Lopez C, Farre M, Roset PN, et al. 3,4- Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. J Pharmacol Exp Ther 2002;300:236 - 44.